Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen L Reckamp

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
Targeted Therapy for Patients With Metastatic Non-Small Cell Lung CancerKaren L Reckamp
Thoracic Surgery Clinics|April 25, 2020
Molecular Targets Beyond the Big 3Karen L Reckamp
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Advances in immunotherapy for non-small cell lung cancerKaren L Reckamp
Cancer Letters|February 7, 2012
Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancerKaren L Reckamp
Seminars in Oncology|November 26, 2008
Non-small cell lung cancer in the elderly: defining treatment optionsNilesh Vora, Karen L Reckamp
Seminars in Respiratory and Critical Care Medicine|May 26, 2020
Immunotherapy in Advanced Non-Small Cell Lung CancerJoy Huang, Karen L Reckamp
Oncology (Williston Park, N.Y.)|July 17, 2020
Immunotherapy in Advanced Lung CancerJoy Huang, Karen L Reckamp
Expert Opinion on Biological Therapy|May 15, 2025
An evaluation of patritumab deruxtecan for the treatment of <i>EGFR</i>-mutated non-small cell lung cancerBarliz Waissengrin, Karen L Reckamp
Maturitas|February 8, 2011
Management of non-small-cell lung cancer in the older adultAri VanderWalde, Sumanta Kumar Pal, Karen L Reckamp
Anti-Cancer Drugs|March 25, 2024
Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancerMarion Ferreira, Matthew I Ebia, Karen L Reckamp
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
Targeted Therapy for Patients With Metastatic Non-Small Cell Lung CancerKaren L Reckamp
Thoracic Surgery Clinics|April 25, 2020
Molecular Targets Beyond the Big 3Karen L Reckamp
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Advances in immunotherapy for non-small cell lung cancerKaren L Reckamp
Cancer Letters|February 7, 2012
Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancerKaren L Reckamp
Seminars in Oncology|November 26, 2008
Non-small cell lung cancer in the elderly: defining treatment optionsNilesh Vora, Karen L Reckamp
Seminars in Respiratory and Critical Care Medicine|May 26, 2020
Immunotherapy in Advanced Non-Small Cell Lung CancerJoy Huang, Karen L Reckamp
Oncology (Williston Park, N.Y.)|July 17, 2020
Immunotherapy in Advanced Lung CancerJoy Huang, Karen L Reckamp
Expert Opinion on Biological Therapy|May 15, 2025
An evaluation of patritumab deruxtecan for the treatment of <i>EGFR</i>-mutated non-small cell lung cancerBarliz Waissengrin, Karen L Reckamp
Maturitas|February 8, 2011
Management of non-small-cell lung cancer in the older adultAri VanderWalde, Sumanta Kumar Pal, Karen L Reckamp
Anti-Cancer Drugs|March 25, 2024
Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancerMarion Ferreira, Matthew I Ebia, Karen L Reckamp
Pageof 12